Vaccine "Vaxneuvance"

In children aged 6 weeks and older:

• Prevention of invasive pneumococcal infection, such as:
• Bacteremia (blood infection)
• Meningitis
• Pneumonia
• Prevention of acute otitis media (ear infection)

In adults (including ≥18 years):

• Prevention of invasive diseases, including:
• Pneumonia
• Sepsis
• Meningitis

Special groups for whom the vaccine is recommended:

• Individuals with chronic medical conditions (e.g., diabetes, COPD, heart failure)
• Individuals with immunosuppression (post-transplant, HIV, chemotherapy)
• Elderly people (65 years and older)
• Individuals with anatomical or functional asplenia (absent or non-functional spleen)

Hypersensitivity to: The active substance (pneumococcal polysaccharides conjugated to CRM ₁₉₇ ) Any excipient in the vaccine (e.g. polysorbate 80, histidine) Other pneumococcal vaccines (if there was an allergic reaction previously)

Anaphylactic reaction after a previous dose of Vaxnewance vaccine or any vaccine containing the same protein carrier (CRM ₁₉₇ ).

Acute infectious diseases with elevated body temperature (fever ≥38°C):
In this case, vaccination is postponed until recovery.

In children (usually occurring within 1–3 days after vaccination) :

• Increased body temperature (fever)
• Irritability, crying
• Decreased appetite
• Drowsiness or sleep disturbances
• Redness, swelling, or pain at the injection site

In adults:

• Pain at the injection site (up to 60% of cases)
• Weakness, fatigue
• Headache
• Muscle or joint pain
• Slight increase in temperature
• Swelling or hardness at the injection site